#USA #San Diego #Actimab-A #Actinium Pharmaceuticals #ATNM-400

Actinium Pharmaceuticals Unveils New Developments in Radiotherapy at AACR 2026

Actinium Pharmaceuticals, a front-runner in the field of targeted radiotherapies, is set to present groundbreaking preclinical data at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting scheduled for April 17-22 in San Diego, California. The data, which underscores the immense potential of the company’s ATNM-400 radioconjugate and highlights a differentiated mechanism for its Actimab-A treatment, promises to be a significant contribution to the ongoing dialogue on cancer treatment advancements.

Highlights of the New Data

The preclinical findings presented by Actinium showcase the efficacy of ATNM-400 across various solid tumor models, demonstrating first-in-class potential as an Ac-225 radioconjugate. This innovative therapy has shown remarkable activity, even in tumors that exhibit resistance to conventional targeted therapies. Actinium's Chairman and CEO, Sandesh Seth, emphasized that these developments validate the strength and adaptability of their Ac-225 radiotherapy platform.

Additionally, the presentation of Actimab-A will include insights into its mutation-agnostic mechanism, related to its ability to enhance the response to standard therapies for acute myeloid leukemia (AML). This revolutionary approach indicates not just the versatility of Actimab-A but also its promise in improving therapeutic outcomes.

Specifics of the AACR 2026 Presentations

The presentations will occur on April 21, 2026 during the Radiopharmaceutical Platforms for Theranostic Precision Oncology session. The details of the posters are as follows:

• - ATNM-400: Poster Number 5824, scheduled from 2:00 PM - 5:00 PM PT, Board #18.
• - Actimab-A: Poster Number 5827, also slated for 2:00 PM - 5:00 PM PT, Board #21.

These sessions will provide an invaluable opportunity for attendees to engage with the latest innovations in cancer treatment technologies.

About Actinium Pharmaceuticals

Founded with a mission to revolutionize cancer treatment, Actinium Pharmaceuticals focuses on developing innovative radioconjugates that enhance therapeutic efficacy while minimizing harm to healthy tissues. The company leverages expertise in fields ranging from tumor biology to radiochemistry. Actinium's strategic pipeline includes:
1. Solid tumor therapies, particularly ATNM-400 and Actimab-A, that show potential across a range of tumor types.
2. Actimab-A as a core treatment for AML and myelodysplastic syndromes (MDS) in collaboration with the National Cancer Institute (NCI).
3. Development of targeted conditioning agents for various therapies, including Iomab-B and Iomab-ACT.

The company holds approximately 250 patents and patent applications pertaining to various aspects of their products, underlining their commitment to innovation in cancer therapy.

Conclusion

With the forthcoming presentations in San Diego, Actinium Pharmaceuticals aims to share its latest advancements in the fight against cancer with a broader audience. The data not only highlights the promising future of both ATNM-400 and Actimab-A but also reinforces their mission of transforming cancer treatment through effective, science-driven approaches.

For continuous updates and more detailed insights, visit Actinium's official website at www.actiniumpharma.com.

Forward-Looking Statements: This announcement includes forward-looking statements regarding potential future results and is subject to a variety of risks. Actual results can differ significantly based on numerous factors, including but not limited to regulatory approvals and market reception.